Inhibitors of phosphoinositol 3 kinase and NFκB for the treatment of chronic obstructive pulmonary disease

Recent Patents on Inflammation and Allergy Drug Discovery

Volumn 5, Issue 3, 2011, Pages 178-183

  Larocca, Nancy E ^a   Moreno, Dolores ^a   Garmendia, Jenny V ^a   de Sanctis, Juan B ^a  

^a UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

Author keywords

Alkylamines; Azol pyrimidines derivatives; Chronic obstructive pulmonary disease; Imidazolines; Mtor inhibitors; Nfkb inhibitors; Phosphoinositide 3 kinase; Quinazolines; Triazoles

Indexed keywords

2 (2 DIFLUOROMETHYLBENZIMIDAZOL 1 YL) 4,6 DIMORPHOLINO 1,3,5 TRIAZINE; 2 (6 AMINO 9 PURINYLMETHYL) 5 METHYL 3 (2 METHYLPHENYL) 3H QUINAZOLIN 4 ONE; 2 MORPHOLINO 8 PHENYLCHROMONE; ALIPHATIC AMINE; AS 206828; CORTICOSTEROID DERIVATIVE; FLUNOXAPROFEN; GLUCOCORTICOID RECEPTOR; I KAPPA B; I KAPPA B KINASE INHIBITOR; IMIDAZOLINE DERIVATIVE; KCR 108; LENALIDOMIDE; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MUSCARINIC AGENT; PHOSPHATIDYLINOSITOL 3 KINASE GAMMA; PHOSPHATIDYLINOSITOL 3 KINASE INHIBITOR; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; QUINAZOLINE DERIVATIVE; SCATTER FACTOR RECEPTOR; THALIDOMIDE; THALIDOMIDE DERIVATIVE; THEOPHYLLINE; THIAZOLE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UREA DERIVATIVE; WORTMANNIN;

ANTIINFLAMMATORY ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; NONHUMAN; PATENT; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PROTEIN SYNTHESIS INHIBITION; REVIEW; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; HUMANS; IMIDAZOLINES; NF-KAPPA B; PATENTS AS TOPIC; PHOSPHATIDYLINOSITOL 3-KINASES; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STEROIDS; TOR SERINE-THREONINE KINASES;

EID: 80052842965     PISSN: 1872213X     EISSN: None     Source Type: Journal    
DOI: 10.2174/187221311797264928     Document Type: Review

References (61)

1. Global Strategy for Diagnosis, Management and Prevention of COPD Updated 2009. Global Initiative for Chronic Obstructive Lung Disease. http://www.goldcopd.org. [Accessed on:March 23, 2011].
2. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8(3): 183-92.
3. Barnes PJ. New therapies for chronic obstructive pulmonary disease. Med Princ Pract 2010; 19(5): 330-8.
4. Larocca NE, Moreno D, Garmendia JV, De Sanctis JB. New Pharmacologic treatments fro patients with chronic obstructive pulmonary disease (COPD). Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 2011; 155(1): 43-50.
5. Marone R, Cmiljanovic V, Giese B, Giman MP. Targeting phosphoinositide 3-kinase. Moving towards therapy. Biochim Biophys Acta 2008; 1784: 159-85.
6. Marwick JA, Chung KF, Adcock IM. Phosphatidylinositol 3-kinase isoforms as targets in respiratory disease. Ther Adv Respir Dis 2010; 4: 19-34.
7. Fung-Leung WP. Phosphoinositide 3-kinase delta (PI3K) in leukocyte signaling and function. Cell Signal 2011; 23(4): 603-8.
8. Kurig B, Shymanets A, Bohnacker T, Prajwal BC, Ahmadian MR, Schaefer M, et al. Ras is an indispensable coregulator of the class IB phosphoinositide 3-kinase p87/p110gamma. Proc Natl Acad Sci USA 2009; 106(48): 20312-7.
9. Balla T. Finding partners for PI3Kgamma: When 84 is better than 101. Sci Signal 2009; 2(74): pe35.
10. Bohnacker T, Marone R, Collmann E, Calvez R, Hirsch E, Wymann MP. PI3Kgamma adaptor subunits define coupling to degranulation and cell motility by distinct PtdIns(3,4,5)P3 pools in mast cells. Sci Signal 2009; 2(74): ra27.
11. Takeda M, Ito W, Tanabe M, Ueki S, Kihara J, Kato H, et al. The pathophysiological roles of PI3Ks and therapeutic potential of selective inhibitors in allergic inflammation. Int Arch Allergy Immunol 2010; 152 (suppl 1) 90-5.
12. To Y, Ito K, Kizawa Y, Failla M, Ito M, Kusama T, et al. Targeting phosphoinositide-3-kinase-delta with theophylline reverses corticosteroid insensitivity in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(7): 897-904.
13. Mercado N, To Y, Ito K, Barnes PJ. Nortriptyline reverses corticosteroid insensitivity by inhibition of PI3K-{delta}. J Pharmacol Exp Ther 2011; 337(2): 465-70.
14. Venable JD, Ameriks MK, Blevitt JM, Thurmond RL, Fung-Leung WP. Phosphoinositide 3-kinase gamma (PI3Kgamma) inhibitors for the treatment of inflammation and autoimmune disease. Recent Pat Inflamm Allergy Drug Discov 2010; 4(1): 1-15.
15. Williams O, Houseman BT, Kunkel EJ, Aizenstein B, Hoffman R, Knight ZA, et al. Discovery of dual inhibitors of the immune cell PI3Ks p110delta and p110gamma: A prototype for new anti-inflammatory drugs. Chem Biol 2010; 17(2): 123-34.
16. Fowler, K.W., Huang, D., Kesicki, E.A., Ooi, H.C., Oliver, A., Ruan, F., Treiberg, J. Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta. US20100256167 & US20100256168 (2010).
17. Stauffer, F., Furet, P. 2,4-Substituted quinazolines as lipid kinase inhibitors. US20090258882 (2009).
18. Evars, J., Ulrich, R.G. Atropisomers of 2-purinyl-3-tolyl-quina-zolinone derivatives and methods of use. US20100249155 (2010).
19. Castanedo, G., Goldstein, D., Kondru, R., Lucas, M., Palmer, W., Price, S., Safina, B., Savy, P.P.A., Seward, E.M., Sutherlin, D.P., Sweeney, Z.K. Bicyclic indole-pyrimidine PI3K inhibitor compounds selective for p110 delta, and methods of use. US20100305084 & US20100305096 (2010).
20. Ni, Z.-J., Pecchi, S., Burger, M., Han, W., Smith, A., Atallah, G., Bartulis, S., Frazier, K., Verhagen, J., Zhang, Y., Iwanowicz, E., Hendrickson, T., Knapp, M., Merritt, H., Voliva, C., Wiesmann, M., Legrand, D.M., Bruce, I., Dale, J., Lan, J., Levine, B., Costales, A., Liu, J., Pick, T., Menezes, D. PI3 kinase inhibitors and methods of their use. US20100075965 (2010).
21. Thompson, N.T., Lyons, J.F., Boyle, R.G., Grimshaw, K.M., Garrett, M.D., Collins, I. Pharmaceutical combinations of PK inhibitors and other active agents. US20090082370 (2009).
22. Fjellstrom, O., Gustafsson, D., Lindberg, J., Jackson, S. Enantiomerically pure (-) 2-[1-(7-methyl-2-(morpholin-4-yl)-4-oxo-4h-pyrido[1,2-a]pyrimidin-9-yl)ethylamino]benzoic acid, its use in medical therapy, and a pharmaceutical composition comprising it -026.US20090191177 (2009).
23. Shimada, M., Murata, T., Fuchikami, K., Tsujishita, H., Omori, N., Kato, I., Miura, M., Urbahns, K., Gantner, F., Bacon, K. Fused azole-pyrimidine derivatives. US7511041 (2009).
24. Capraro, H.G., Furet, P., Imbach, P., Stauffer, F. Imidazo-pyridazines as lipid kinase inhibitors. US20090318410 (2009).
25. White, S.L., Kesicki, E.A., Thorsett, E., Ruan, F., Farouz, F. Thienopyrimidiones for treatment of inflammatory disorders and cancers.US20100216820 (2010).
26. Berdini, V., Boyle, R.G., Saxty, G., Walker, D.W., Woodhead, S.J., Wyatt, P.G., Donald, A., Caldwell, J., Collins, I., Da Fonseca, T.F. Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors. US20090247538 (2009).
27. Cho SY, Han SY, Ha JD, Ryu JW, Lee CO, Jung H, et al. Discov-ery of aminopyridines substituted with benzoxazole as orally active c-Met kinase inhibitors. Bioorg Med Chem Lett 2010; 20 (14): 4223-7.
28. Thompson AM, Delaney AM, Hamby JM, Schroeder MC, Spoon TA, Crean SM, et al. Synthesis and structure-activity relationships of soluble 7-substituted 3-(3,5-dimethoxyphenyl)-1,6-naphthyridin-2-amines and related ureas as dual inhibitors of the fibroblast growth factor receptor-1 and vascular endothelial growth factor re-ceptor-2 tyrosine kinases. J Med Chem 2005; 48(14): 4628-53.
29. Burger, M., Ni, Z.J., Pecchi, S., Atallah, G., Bartulis, S., Frazier, K., Smith, A., Verhagen, J., Zhang, Y., Wagman, A., Ng, S., Pfister, K., Poon, D.J., Louie, A., Pick, T., Barsanti, P., Iwanowicz, E., Fantl, W., Hendrickson, T., Knapp, M., Meritt, H., Voliva, C., Wiesmann, M., Xin, X. Pyrimidine derivatives used as PI-3-kinase inhibitors. US20100249126 (2010).
30. Blomfield, G.C., Bruce, I., McCarthy, C., Finan, P., LeBlanc, C., Whitehead, L., Press, N., Hayler, J., Kirman, L., Oza, M.S., Shukla, L. 5-Phenylthiazole derivatives and use as PI3 kinase inhibitors. US20100093690 (2010).
31. Bruce, I., Finan, P., Leblanc, C., McCarthy, C., Whitehead, L., Press, N., Bloomfield, G.C., Hayler, J., Kirman, L., Oza, M.S., Shukla, L. 5-Phenylthiazole derivatives and use as PI3 kinase in-hibitors. US7687637 (2010).
32. Wilson, F., Ramsden, N., Bell, K., Cansfield, A., Burckhardt, S., Taylor, J., Sunose, M., Middlemiss, D. Triazole derivatives as kinase inhibitors. US20100227800 (2010).
33. Ramsden, N., Bell, K., Cansfield, A.D., Taylor, J., Sunose, M., Middlemiss, D., Neubauer, G. Amino triazoles as PI3k inhibitors. US20110021497 (2011).
34. Kong D, Yamori T. Advances in development of phosphatidyli-nositol 3-kinase inhibitors. Curr Med Chem 2009; 16(22): 2839-54.
35. Kong DX, Yamori T. ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor identified using the JFCR39 drug discovery sys-tem. Acta Pharmacol Sin 2010; 1(9): 1189-97.
36. Han SY, Lee CO, Ahn SH, Lee MO, Kang SY, Cha HJ, et al. Evaluation of a multi-kinase inhibitor KRC-108 as an anti-tumor agent in vitro and in vivo. Invest New Drugs 2010 [Epub aheadof print].
37. Ferrand, S., Glickman, F., Leblanc, C., Ritchie, C., Shaw, D., Stiefl, N.J., Furet, P., Imbach, P., Stauffer, F., Capraro, H.G., Gessier, F., Gaul, C., Albaugh, P.A., Chopiuk, G. Heterocyclic compounds as antiinflammatory agents. US20100041662 (2010).
38. Woodhead, S.J., Downham, R., Hamlett, C., Howard, S., Sore, H.F., Verdonk, M.L., Walker, D.W., Luke, R.W.A. Aryl-alkylamines and heteroaryl-alkylamines as protein kinase inhibitors. US20100210617 (2010).
39. Hamblin, J.N., Jones, P.S., Keeling, S.E., Le, J., Mitchell, C.J., Parr, N.J. Novel compounds. US20100280029 (2010).
40. Onoue S, Misaka S, Kwabata Y, Yamada S. New treatments for chronic obstructive pulmonary disease and viable formulation/ de-vice options for inhalation therapy. Expert Opin Drug Deliv 2009; 6(8): 793-801.
41. Doukas J, Eide L, Stebbins K, Racanelli-Layton A, Dellamary L, Martin M, et al. Aerosolized phosphoinositide 3-kinase gamma/ delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl) pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease. J Pharmacol Exp Ther 2009; 328(3): 758-65.
42. Yuan, H., Luo, J., Weissleder, R., Cantley, L., Josephson, L. Wortmannin conjugates and uses thereof. US20090324489 (2009).
43. Meggers, E., Marmorstein, R., Xie, P., Williams, D.S. Metal com-plex phosphatidyl-inositol-3-kinase inhibitors. US20090275547 (2009).
44. Sadhu, C., Dick, K., Treiberg, J., Sowell, G.C., Kesicki, E.A., Oliver, A. Inhibitors of human phosphatidyl-inositol 3-kinase delta. US20100152211 (2010).
45. White, S.L., Ruan, F., Kesicki, E.A., Thorsett, E., Farouz, F. Inhibitors of human phosphatidyl-inositol 3-kinase delta. US20110021541 (2011).
46. Atallah, G., Bartulis, S., Burger, M., Merritt, H., Ng, S., Ni, Z.J., Pecchi, S., Pfister, K.B., Smith, A., Voliva, C., Wagman, A., Zhang, Y. PI3-kinase inhibitors and methods of their use. US20100048547 (2010).
47. Budd, E., Hayler, J.F., Bruce, I., Legrand, D.M., Cox, B. 5-Phenyl-thiazol-2-yl-urea derivatives and use as PI3 kinase inhibitors. US20090234132 (2009).
48. Andrews, K., Bo, Y.Y., Booker, S., Cee, V.J., D'angelo, N., Herberich, B.J., Hong, F.T., Jackson, C.L.M., Lanman, B.A., Liao, H., Liu, L., Nishimura, N., Norman, M.H., Pettus, L.H., Reed, A.B., Smith, A.L., Tadesse, S., Tamayo, N.A., Wu, B., Wurz, R., Yang, K. Inhibitors of PI3 kinase and/or mTOR. US20100273764 (2010).
49. Brody, J.S., Spira, A., Gustafson, A., Bild, A. Identification of novel pathways for drug development for lung disease. US20090186951 (2009).
50. Ren, P., Liu, Y., Wilson, T.E., Li, L., Chan, K. Benzoxazole kinase inhibitors and methods of use. US20100190749 & US20100184760 (2010).
51. Rossi F, Filippelli A, Stella L, Vacca C, Lampa E. Effects of flunoxaprofen, a non-steroidal anti-inflammatory agent, on the car-diovascular system. J Med 1992; 23(5): 315-26.
52. De Sanctis JB, Mijares M, Suárez A, Compagnone R, Garmendia J, Moreno D, et al. Pharmacological properties of thalidomide and its analogues. Recent Pat Inflamm Allergy Drug Discov 2010; 4(2): 144-8.
53. Herman SE, Lapalombella R, Gordon AL, Ramanunni A, Blum KA, Jones J, et al. The role of phosphatidylinositol 3-kinase-{delta} in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia. Blood 2011 117(16): 4323-7.
54. Marwick JA, Caramori G, Casolari P, Mazzoni F, Kirkham PA, Adcock IM, et al. A role for phosphoinositol 3-kinase delta in the impairment of glucocorticoid responsiveness in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol. 2010; 125(5): 1146-53.
55. Marwick JA, Adcock IM, Chung KF. Overcoming reduced gluco-corticoid sensitivity in airway disease: Molecular mechanisms and therapeutic approaches. Drugs 2010; 70(8): 929-48.
56. Edwards MR, Bartlett NW, Clarke D, Birrell M, Belvisi M, Johnston SL. Targeting the NF-B pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009; 121: 1-13.
57. Rajendrasozhan S, Chung S, Sundar IK, Yao H, Rahman I. Tar-geted disruption of NF-{kappa}B1 (p50) augments cigarette smoke-induced lung inflammation and emphysema in mice: A critical role of p50 in chromatin remodeling. Am J Physiol Lung Cell Mol Physiol 2010; 298(2): L197-209.
58. Brown V, Elborn JS, Bradley J, Ennis M. Dysregulated apoptosis and NFkappaB expression in COPD subjects. Respir Res 2009; 10: 24.
59. Tepe, J.J. NF-kB inhibitors and uses thereof. US20080114015 (2008).
60. Boehm, J.C., Busch-Petersen, J., Fu, W., Jin, Q., Kerns, J.K., Li, H., Lin, G., Lin, X., Neipp, C.E. Indole carboxamides as IKK2 inhibitors. US20100130468 (2010).
61. Dev, I.K., Subbiah, V. Triterpene derivatives for the treatment of cancer and inflammatory disease by inhibition of NF-KAPPAB. US20090036524 (2009).